• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New Guidance for Multiregional Clinical Trials

New Guidance for Multiregional Clinical Trials

July 23, 2018
William Myers

The FDA has issued new guidelines designed to help researchers navigate sometimes conflicting regional requirements and differences in global clinical trials in an effort to pave the way for better cooperation and faster international drug development.

There currently is no single set of rules governing how multiregional clinical trials (MRCTs) should be crafted. But the FDA is hoping to help make the road less bumpy with this fresh ICH E17 addendum.

Among its key recommendations: Plan ahead to make sure an international study is the best route to take. That is, assess potential challenges and regional differences — like environment, diet, cultural twists — to make sure they’re not too great to overcome or skew findings.

Consider all potential factors —and ways to account or adjust for them (by doing genetic testing, for example), the FDA advises, noting that “even in the case of expected major differences ... it may still be possible to conduct MRCTs by excluding some regions or a defined subgroup within a region.”

Your best bet for smooth sailing if you do opt for international probes?

Design them with seven principles in mind, the FDA suggests:

  • Identify early how different regional factors can affect drug trials.
  • Clear communication between sponsors, sites and regulators is a must.
  • Make sure study designs meet all relevant international quality rules for trial planning, investigator training and monitoring.
  • Stay focused on a single analysis so trials pass regulatory muster across regions.
  • Make sure treatment is consistent across the aboard.
  • Pre-plan pooling regions or subpopulations to provide flexibility in sample sizes.
  • Strategically use trials to up drug development efficiency.

Multiregional trials have historically been used as a quick way to recruit participants with rare diseases or in special populations (like children or the elderly) or for large-scale studies (such as vaccine safety and effectiveness). But sponsors increasingly have found they’re an efficient way to get more drugs to more people — and they’re fast becoming the preferred choice for investigating new meds in today’s global market.

The difficulty is that disease definitions, diagnostic methods, medical practices, diet and other factors may vary from region to region, complicating global trials. Given all the potential differences at play, it’s vital to create an ongoing system of quality checks.

“Centralized and risk-based monitoring may be particularly useful for MRCTs to monitor and mitigate the impact of emerging regional difference in, for example, trial subject retention or adverse event reporting,” the FDA says. “Timely and accurate flow of information should occur between the sponsor, the trial management team and the participating sites.”

If investigators take the recommended steps and still notice different regional effects, the FDA suggests conducting “a structured exploration” to try to pin down potential culprits.

During their probe, researchers should consider the usual suspects first – things like disease severity and participants’ race, weight and lifestyle (smoker/nonsmoker, for instance). If that fails to turn up answers, the FDA says, they may need to dig deeper —and perhaps cull data from other clinical trials and sources.

Read the FDA’s guidance here: fdanews.com/07-18-18-ClinicalTrials.pdf.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing